

10982637

AUG 12 1998

**510 (k) Summary
Safety and Effectiveness**

This summary of safety and effectiveness information has been prepared in accordance with the requirements of SMDA 1990 and 21 CFR Part 807.92.

Name: Diagnostic Products Corporation
Address: 5700 West 96th Street
 Los Angeles, California 90045-5597

Telephone Number: (213) 776-0180
Facsimile Number: (213) 776-0204

Contact Person: Edward M. Levine, Ph.D.
 Director of Clinical Affairs

Date of Preparation: July 28, 1998

Device Name: IMMULITE® PSA Control Module
Trade: Device intended as an aid in monitoring the performance of DPC's IMMULITE and IMMULITE 2000 PSA assays.

Catalog Number: LPSCM

Classification: Class I device, 75-JJY (21 CFR 862.1660)

Manufacturer: Diagnostic Products Corporation (DPC)
 5700 West 96th Street
 Los Angeles, CA 90045-5597

Establishment Registration #: 2017183


Description of Device: Quality Control Material

Intended Use of the Device: IMMULITE PSA Control Module is an assayed, tri-level control intended for use with the IMMULITE PSA and IMMULITE 2000 PSA assays. It is intended as an aid in monitoring day-to-day assay performance.


Clinical Studies: Not applicable

Conclusion:

The data presented in this summary of safety and effectiveness is the data that the Food and Drug Administration used in granting DPC substantial equivalence for IMMULITE[®] PSA Control Module.



Edward M. Levine, Ph.D.
Director of Clinical Affairs



Date



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

AUG 12 1998

Food and Drug Administration
2098 Gaither Road
Rockville MD 20850

Edward M. Levine, Ph.D.
Director of Clinical Affairs
Diagnostic Products Corporation
5700 West 96th Street
Los Angeles, California 90045-5597

Re: K982637
Trade Name: IMMULITE® PSA Control Module
Regulatory Class: I
Product Code: JJY
Dated: July 28, 1998
Received: July 29, 1998

Dear Dr. Levine:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.


If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

Page 2

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597, or at its internet address "<http://www.fda.gov/cdrh/dsma/dsmamain.html>".

Sincerely yours,



Steven I. Gutman, M.D., M.B.A.
Director
Division of Clinical
Laboratory Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure